Regenxbio hits 7-month high following $1.75bn partnership with AbbVie
RGNX: REGENXBIO Inc. 2020-08-25 07:00:00 REGENXBIO Announces FDA Clearance of IND for Phase II Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
I strongly believe this is going higher - has cash and have good enough catalyst for 2H, 2020 for it to run up. Good luck
Broke its downtrend, looks like a decent retest of the uptrend.
once again i have no idea what i'm doing.
RGNX sold off 12% today on news of a partial clinical hold on an NVS gene therapy trial using its vector. After reading the press release I think this was an overreaction and the stock price will bounce back swiftly into RGNX earnings catalyst on 11/08/2019. It is sold off right to the bottom of its channel making for a beautiful setup!
This year has been full of positive catalysts for RGNX. As RGNX continues to build out their clinical pipeline, data catalyst from upcoming phase 2a report on their Wet-AMD gene therapy product could send the stock roaring higher. RGNX is set to report data Oct. 13, 2019 and the companies technical setup is quite nice. The Wet-AMD market is a lucrative opportunity...
The prices are around the 200 weekly SMA. From thet level is possible a bound.
RGNX and Novartis just received FDA approval of Gene Therapy treatment for Spinal Muscular Atrophy (SMA). (SMA)Spinal Muscular Atrophy is a disease affecting the motor nerve cells in the spinal cord, taking away the ability to walk, eat, or breathe. It is the number one genetic cause of death for infants. According to a company filling, price tag for...
I would take SL as 45.5 if you go big or SL as 42 if you can bear the loss on small size.
Some potential profit targets and short entries listed above. Short targets listed below.